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The influence of a natural pulmonary surfactant on antibiotic activity was investigated to assess the possible
use of exogenous surfactant as a vehicle for antibiotic delivery to the lung. The influence of surfactant on the
bactericidal activity of amoxicillin was tested against Staphylococcus aureus and Streptococcus pneumoniae, and
the influence of surfactant on the activities of ceftazidime and tobramycin was tested against Klebsiella
pneumoniae, Pseudomonas aeruginosa, S. aureus, and S. pneumoniae. In vitro antibiotic activity was determined
by killing curve studies in media with and without surfactant. Amoxicillin and ceftazidime activities were not
changed in the presence of surfactant, except for a decreased killing rate of S. pneumoniae by ceftazidime in
medium with additional rabbit serum. In contrast, killing curves with low concentrations of tobramycin (0.253
and 13 the MIC) showed a decreased level of activity of tobramycin against all pathogens tested in the
presence of surfactant. With higher tobramycin concentrations (43 the MIC) killing rates were decreased less
or were unchanged in the presence of surfactant. Concluding from the results of the study, both amoxicillin and
ceftazidime can be combined with surfactant without the loss of activity. For mixing surfactant with tobra-
mycin, dosages should be adjusted to overcome the partial inactivation of tobramycin by surfactant.
Lower respiratory tract infections remain an important
cause of morbidity and mortality, despite the use of new potent
antibiotics. Nosocomial pneumonia remains an infection that is
especially difficult to treat, with crude mortality rates of 10 to
30% and even higher rates in specific patient groups (9, 43).
Efficient antimicrobial therapy is considered to be dependent
on appropriate antibiotic concentrations at the site of infection
(1, 43). For pneumonia this is within the alveolar space, to-
gether with the epithelial lining fluid and the lung interstitium
(40). However, the high systemic doses of some antibiotics
needed to reach therapeutic levels at these sites may be ac-
companied by adverse side effects, e.g., oto- and nephrotoxic-
ities caused by aminoglycosides (17, 42).
Local administration of antibiotics via the trachea offers the
potential benefits of delivering high antibiotic concentrations
to the site of infection and low systemic absorption. Previous
studies have shown beneficial effects from both the inhalation
of antibiotics via aerosol (14, 32, 35) and the direct endotra-
cheal instillation of antibiotics (4, 5, 22). However, with aerosol
inhalation the amount of antibiotics deposited in the lung is
small (only 10 to 20%), even with the best nebulizers (4, 16,
25). Moreover, pulmonary deposition is particularly high in the
central airways and decreases toward the periphery in patients
with decreased pulmonary function (16, 24). With direct en-
dotracheal instillation, distribution is also largely limited to the
central airways (3). Thus, the therapeutic efficacies of these
modes of administration are limited, especially since the loca-
tion of infected areas is most often peripheral. The efficacies of
locally administered antibiotics might therefore be improved
by optimizing the distribution within the lung.
Because of the small diameters of the airways in the periph-
ery of the lung, fluids with a high surface tension, such as
saline, require high pressures for passage through these air-
ways (27). Surfactant, a mixture of phospholipids and specific
surfactant proteins, has the capacity to lower surface tension
(44). Recently, it has been shown that use of an exogenous
pulmonary surfactant labelled with a radioactive colloid and
mixed with pentamidine results in a more peripheral and uni-
form distribution pattern in the lungs compared with that ob-
tained with a combination of pentamidine and saline (21). It is
therefore expected that the use of surfactant as a carrier for
antibiotics has great potential in treating patients with severe
pneumonia.
However, it is unknown if surfactant affects the activities of
antibiotics. Therefore, an in vitro study was designed to inves-
tigate the influence of a bovine surfactant on the bactericidal
activities of clinically relevant antibiotics against pathogens
often involved in respiratory tract infections.
MATERIALS AND METHODS
Bacteria and preparation of inoculum. The following strains were used: Kleb-
siella pneumoniae ATCC 43816, Staphylococcus aureus ATCC 25923, Streptococ-
cus pneumoniae ATCC 6301, and Pseudomonas aeruginosa ATCC 27853. For S.
aureus and K. pneumoniae, stationary-phase cultures were prepared by incuba-
tion for 16 h at 378C in Mueller-Hinton broth (MHB; Difco Laboratories,
Detroit, Mich.). For P. aeruginosa, MHB was supplemented with magnesium
(12.5 mg/liter) and calcium (20 to 25 mg/liter) (Merck, Darmstadt, Germany)
(33). After proper dilution and reincubation for 2 h at 378C, suspensions of
logarithmically growing bacteria were obtained. For an S. pneumoniae inoculum,
an overnight culture on a 5% blood agar plate (Bactim, Breukelen, The Neth-
erlands) was suspended in Todd-Hewitt broth (THB; Oxoid Ltd., Basingstoke,
England) containing 10% normal rabbit serum (Dako A/S, Glostrup, Denmark),
which was first inactivated for 30 min at 568C. The culture was then incubated at
378C, and the optical density was measured repeatedly. When the optical density
remained constant for 30 min, the culture was diluted with THB to obtain the
proper inoculum size of end-log-phase bacteria.
Antibiotics. Tobramycin (Eli Lilly, Amsterdam, The Netherlands), amoxicillin
(SmithKline Beecham, Amstelveen, The Netherlands), and ceftazidime (Glaxo
Pharmaceuticals Ltd., Greenford, England) were kindly provided by the manu-
facturers and were prepared by diluting the standard powder or solution with the
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recommended diluent to a stock solution of 2,560 mg/ml, which was stored at
2808C in small aliquots. For each experiment a fresh aliquot was used and was
diluted in broth to obtain the appropriate concentrations.
Surfactant. The surfactant used in the studies was a freeze-dried natural
surfactant isolated from bovine lungs as described previously (13). It consisted of
approximately 90 to 95% phospholipids, 1% hydrophobic proteins (surfactant
proteins B and C), and 1% free fatty acids, the remainder being other lipids such
as cholesterol and glyceride; there was no surfactant-protein A in this surfactant
preparation. For every killing curve study or bacterial growth study, the surfac-
tant was suspended in broth to a concentration of 25 mg/ml of growth medium.
Antimicrobial susceptibility tests. The MIC was determined by a microdilu-
tion technique. The MIC of the drug was defined as the lowest concentration that
suppressed visible growth after incubation of 5 3 105 CFU/ml for 18 h at 378C
in microtiter plates containing a total volume of 200 ml. For K. pneumoniae and
S. aureus this was determined in MHB, for P. aeruginosa this was determined in
MHB supplemented with Mg21 and Ca21, and for S. pneumoniae this was
determined in THB. MICs did not differ by more than one step from the MICs
for these strains reported earlier (28, 36).
Time-kill curves were made at 0.253, 13, and 43 the MIC of the tested
antibiotic. Killing curves were calculated from growth in 10-ml glass tubes con-
taining a total volume of 2 ml of growth medium, with or without 25 mg of
surfactant per ml. For S. pneumoniae, the influence of surfactant on bacterial
killing by antibiotics was determined in THB with and without 10% rabbit serum.
With each assay appropriate growth controls were studied. The starting inoculum
(at time zero) was adjusted to approximately 5 3 105 CFU/ml. Sampling was
performed at 0, 1, 2, 4, 6, and 8 h after inoculation. Tenfold dilution steps of
100-ml samples were made in phosphate-buffered saline (pH 7.3; Oxoid Ltd.,
Basingstoke, England) on ice. In order to determine the number of viable
microorganisms, 100 ml of the appropriate 10-fold dilution steps was plated on
Iso-Sensitest agar (Oxoid Ltd.) or, in the case of S. pneumoniae, on blood agar
plates. Colony counts were determined after 24 h of incubation at 378C. To
minimize antibiotic carryover on subculture plates, only 50 ml of an undiluted
sample was subcultured directly onto the agar plate. The lower limit of detection
by this method was 20 CFU/ml, and the number that could be accurately counted
was 600 CFU/ml. Killing curve studies were performed at least in duplicate.
Other measurements. The pH of the incubation medium was measured to
assess a possible change in pH when surfactant and/or rabbit serum was added to
the broth. For this, volumes of 2 ml of broth with or without 25 mg of surfactant
per ml and with or without 10% rabbit serum were freshly made in duplicate. The
pHs of these samples were measured with a glass electrode (model 920 A; Orion
Research Inc., Boston, Mass.).
The nonbound tobramycin concentrations in samples with and without sur-
factant and with or without rabbit serum in THB were determined in duplicate
by using the Amicon micropartition system (MPS-1, 4010; Amicon, Danvers,
Mass.). For this, 1-ml samples were made. These samples contained approxi-
mately 100 mg of tobramycin and the following: (i) no extra additions (controls),
(ii) 25 mg of surfactant per ml, (iii) 12.5 mg of surfactant per ml, and (iv) 10%
rabbit serum. The samples were centrifuged at 2,000 3 g for 30 min. Tobramycin
concentrations were determined for filtration in the sample and after filtration in
the filtrate by fluorescence analysis with the TDX system (Abbott Diagnostic
Division, Weesp, The Netherlands). Binding is expressed as [1 2 (ratio of free
tobramycin/total tobramycin)] z 100%.
Statistical analysis. For analysis of the data, a logarithmic transformation
(log10) was performed on all data. With killing curves, the total area under the
killing curve of transformed data was determined for presentation of the data. In
this type of analysis the rate of killing is inversely related to the area under the
killing curve (41). The effect of surfactant on antibiotic activity (with surfactant
versus without surfactant) was tested by analysis of variance for repeated mea-
sures by using the GLM procedure of the SAS statistical package (39). With
these tests the overall effect of surfactant on antibiotic activity as well as the effect
of surfactant for each antibiotic concentration separately were tested. Addition-
ally, for S. pneumoniae the effect of rabbit serum was tested.
Growth rate was expressed as the slope (y/x) of the regression line from time
zero to 8 h, and the units of growth rate were the change in the log10 CFU per
milliliter per hour (28). The means and standard deviations were calculated.
Statistical significance between the growth rate of bacteria in medium with
surfactant versus that in medium without surfactant was tested by the t test for
two samples (39). With all statistical tests, significance was accepted at P values
of #0.05 (two-tailed).
RESULTS
Bacterial growth rate (log10 CFU per milliliter per hour) was
not altered for P. aeruginosa, K. pneumoniae, or S. aureus in the
presence of surfactant (Table 1). For S. pneumoniae, the bac-
terial growth rate was not affected except for a decreased
growth rate in THB with rabbit serum in the presence of
surfactant (Table 1). No statistically significant difference was
found between the growth rate of S. pneumoniae in THB with
rabbit serum (0.509 6 0.03 log10 CFU/ml/h) and the growth
rate in THB with rabbit serum and surfactant (0.437 6 0.03
log10 CFU/ml/h) compared with the growth rate in THB alone
(P 5 0.064 and 0.606, respectively). Similarly, no statistically
significant difference was found between the growth rate of S.
pneumoniae in THB with rabbit serum (0.509 6 0.03 log10
CFU/ml/h) and the growth rate in THB with rabbit serum and
surfactant (0.437 6 0.03 log10 CFU/ml/h) compared with the
growth rate in THB with surfactant and without serum (0.481
6 0.007 log10 CFU/ml/h) (P 5 0.060 and 0.306, respectively).
Bacterial killing of S. pneumoniae and S. aureus by amoxi-
cillin and of K. pneumoniae, P. aeruginosa, and S. aureus by
ceftazidime was not altered in the presence of surfactant (Ta-
bles 2 and 3). The killing of S. pneumoniae by ceftazidime in
THB supplemented with rabbit serum was decreased in the
presence of surfactant at 43 the MIC (Table 3). A reduction in
the bactericidal activity (increased areas under the killing
curve) of tobramycin against K. pneumoniae, P. aeruginosa, S.
aureus, and S. pneumoniae was observed when surfactant was
added to the medium (Table 4). This was best demonstrated in
killing curves at the MIC for the tested strain. The effect of
surfactant on bacterial killing by tobramycin was less (S. aureus
TABLE 1. Bacterial growth rates
Organism
Bacterial growth rate
(log10 CFU/ml/h [mean 6 SD])
P valuea
Without
surfactant With surfactant
K. pneumoniae 0.524 6 0.084 0.576 6 0.053 0.414
P. aeruginosa 0.349 6 0.018 0.344 6 0.010 0.652
S. aureus 0.474 6 0.048 0.463 6 0.046 0.740
S. pneumoniae
Without serum 0.403 6 0.076 0.481 6 0.007 0.131
With serum 0.509 6 0.025 0.437 6 0.033 0.015
a The P value for bacterial growth in medium with surfactant versus that for
bacterial growth in medium without surfactant was determined by the t test.
TABLE 2. Influence of surfactant on amoxicillin activity
Organism
Amoxicillin
concn
(mg/ml)
Area under killing curve
[(log10 CFU/ml) 3 h
(mean 6 SD)]
P value
Without
surfactant
With
surfactant
Be-
tweena
Over-
allb
S. aureus 0.03 47.99 6 4.46 43.40 6 0.17 0.303 0.774
0.13 29.42 6 1.15 29.29 6 1.12 0.917
0.5 22.88 6 0.17 22.40 6 5.05 0.861
S. pneumoniae
Without serum 0.03 52.32 6 1.80 55.11 6 0.38 0.174 0.393
0.13 29.94 6 0.26 17.28 6 5.76 0.061
0.5 19.77 6 4.53 15.51 6 4.75 0.521
With serum 0.03 53.57 6 0.47 55.72 6 0.36 0.346 0.394
0.13 28.84 6 1.98 26.70 6 1.12 0.717
0.5 19.43 6 4.33 17.39 6 6.40 0.489
a The P values for the effects of surfactant on antibiotic activity for each
antibiotic concentration were determined by analysis of variance for repeated
measures.
b The P values for the effects of surfactant on antibiotic activity in all killing
curves were determined by analysis of variance for repeated measures.
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and S. pneumoniae) or disappeared (K. pneumoniae and P.
aeruginosa) when tobramycin concentrations were increased to
43 the MIC for the tested pathogen (Table 4). Typical exam-
ples of decreased tobramycin activity in the presence of sur-
factant against S. pneumoniae and K. pneumoniae are shown in
Fig. 1 and 2, respectively. The addition of rabbit serum to THB
did not alter the overall killing rates of S. pneumoniae by
amoxicillin (P 5 0.647) or ceftazidime (P 5 0.201) compared
with the bacterial killing rate in THB alone. Overall killing by
tobramycin in medium with rabbit serum was decreased com-
pared with killing in THB alone (P , 0.001).
The pH of the incubation medium was not affected by the
addition of surfactant and/or rabbit serum to the broth. The
change in pH was ,0.05 in all experiments. Tobramycin bind-
ing was (i) 13% in THB alone (controls), (ii) 30% in THB plus
25 mg of surfactant per ml, (iii) 19% in THB plus 12.5 mg of
surfactant per ml, and (iv) 21% in THB plus rabbit serum.
Differences between duplicate determinations were,2% in all
experiments.
DISCUSSION
In the present study, the influence of a natural pulmonary
surfactant on antibiotic activity was investigated to assess the
possible use of surfactant as a vehicle for delivering antibiotics
to the lung. The results show that both amoxicillin and cefta-
zidime can be combined with pulmonary surfactant without the
loss of antibiotic activity. Tobramycin activity was reduced in
the presence of surfactant, but this could be overcome by
increasing the tobramycin concentration. Furthermore, it can
be concluded that pulmonary surfactant can alter antibiotic
activity; therefore, antibiotic activity should be tested before
using surfactant-antibiotic mixtures for the treatment of severe
pneumonia.
Several studies have reported the inactivation of aminogly-
cosides, as was found with tobramycin in the present study. The
pH strikingly alters the bioactivities of aminoglycosides. The
MIC increases, depending on the organism and the particular
aminoglycoside involved, when the pH of the culture medium
FIG. 1. Time-kill curves for S. pneumoniae with tobramycin (64 mg/ml 5 43
the MIC) in THB (), THB and rabbit serum (), THB and 25 mg of surfactant
per ml (E), and THB with rabbit serum and surfactant (F). 1, a growth control
in THB.
TABLE 3. Influence of surfactant on ceftazidime activity
Organism
Ceftazidime
concn
(mg/ml)
Area under killing curve
[(log10 CFU/ml) 3 h
(mean 6 SD)]
P value
Without
surfactant
With
surfactant
Be-
tweena
Over-
allb
K. pneumoniae 0.13 19.90 6 0.12 25.17 6 3.08 0.346 0.378
0.5 16.32 6 2.62 17.88 6 2.42 0.717
2 8.30 6 8.20 13.11 6 3.85 0.489
P. aeruginosa 0.5 54.38 6 2.25 51.70 6 5.69 0.337 0.799
2 38.59 6 0.59 38.52 6 0.10 0.409
8 35.23 6 3.08 32.54 6 0.96 0.348
S. aureus 0.03 49.77 6 0.75 43.78 6 3.71 0.184 0.602
0.13 27.74 6 3.13 32.25 6 0.39 0.250
0.5 24.84 6 3.38 30.67 6 0.50 0.158
S. pneumoniae
Without serum 0.03 48.79 6 2.46 52.54 6 0.90 0.100 0.570
0.13 24.51 6 4.23 15.43 6 3.51 0.076
0.5 16.48 6 0.69 15.15 6 0.90 0.198
With serum 0.03 51.92 6 1.49 52.99 6 0.37 0.329 0.003
0.13 22.32 6 5.74 27.90 6 1.41 0.120
0.5 18.41 6 3.53 26.88 6 1.24 0.050
a The P values for the effects of surfactant on antibiotic activity for each
antibiotic concentration were determined by analysis of variance for repeated
measures.
b The P values for the effects of surfactant on antibiotic activity in all killing
curves were determined by analysis of variance for repeated measures.
TABLE 4. Influence of surfactant on tobramycin activity
Organism
Tobramycin
concn
(mg/ml)
Area under killing curve
[(log10 CFU/ml) 3 h
(mean 6 SD)]
P value
Without
surfactant
With
surfactant
Be-
tweena
Over-
allb
K. pneumoniae 0.13 64.48 6 0.80 64.94 6 0.01 0.222 0.001
0.5 13.66 6 0.27 61.92 6 0.31 0.000
2 3.54 6 0.92 4.04 6 1.63 0.742
P. aeruginosa 0.5 25.71 6 4.53 41.22 6 2.45 0.038 0.567
2 5.34 6 3.46 2.89 6 0.00 0.423
8 2.89 6 0.00 2.89 6 0.00 1.000
S. aureus 0.03 51.67 6 4.18 53.13 6 0.99 0.727 0.016
0.13 12.56 6 10.64 39.41 6 15.17 0.169
0.5 6.15 6 1.22 20.81 6 1.57 0.011
S. pneumoniae
Without serum 4 48.67 6 5.03 55.74 6 0.54 0.206 0.001
16 15.23 6 2.67 54.26 6 0.18 0.002
64 4.35 6 0.86 32.73 6 1.19 0.001
With serum 4 55.96 6 2.17 54.86 6 0.38 0.610 0.005
16 54.63 6 1.83 54.49 6 0.14 0.651
64 21.90 6 6.46 39.24 6 0.27 0.001
a The P values for the effects of surfactant on antibiotic activity for each
antibiotic concentration were determined by analysis of variance for repeated
measures.
b The P values for the effects of surfactant on antibiotic activity in all killing
curves were determined by analysis of variance for repeated measures.
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falls below 7.0 (37, 47). Aminoglycoside activity is also influ-
enced by the amount of free unbound cations in the culture
medium (20, 48). Other studies have reported the inactivation
of aminoglycosides in sputum, which could be explained, in
part, by binding of the antibiotic to subcellular components of
sputum (6, 26, 30). Aminoglycosides have been reported to
interact with ribosomes, DNA, and glycoproteins in bronchial
secretions (10, 34, 38).
In the present study, the partial inactivation of tobramycin
cannot be explained by alterations in pH or changes in free
cation concentrations after the addition of surfactant. The pH
did not change after the addition of surfactant to the medium.
The free cation concentration in the surfactant was not mea-
sured. However, changes in free cation concentrations should,
in particular, affect P. aeruginosa killing by tobramycin (2, 46),
whereas in the present study P. aeruginosa killing by tobramy-
cin was least influenced by the surfactant. The reduced killing
by tobramycin is therefore unlikely to be due to differences in
free cation concentrations between the media.
To assess a possible binding of tobramycin with surfactant,
we measured the amount of free drug by centrifugation-filtra-
tion. The amount of tobramycin recovered in the filtration fluid
was decreased most in the presence of 25 mg of surfactant per
ml. Binding of aminoglycosides to negatively charged phospho-
lipids has previously been described as a mechanism for the
nephrotoxic actions of these antibiotics (29, 31). Pulmonary
surfactant comprises 90% phospholipids, mostly phosphatidyl-
choline and phosphatidylglycerol (44). The decreased activity
of tobramycin is therefore possibly induced by the binding of
tobramycin to phospholipids in the surfactant.
We have no explanation for the observed decrease in cefta-
zidime activity against S. pneumoniae in THB supplemented
with rabbit serum. This decrease was found only at 43 the
MIC in medium with rabbit serum. In contrast to these find-
ings, with S. pneumoniae in THB there was a tendency for
increased killing in the presence of surfactant; this was, how-
ever, not statistically significant.
A few studies have investigated the direct influence of pul-
monary surfactant on bacterial growth (8, 18, 19, 23). Coonrod
and Yoneda (8) showed that a surfactant preparation from
bronchoalveolar lavage fluid of rats and, more specifically, the
free fatty acids present in the surfactant caused lysis of S.
pneumoniae. The bactericidal activity of this surfactant prepa-
ration was also observed with several other gram-positive bac-
teria, including viridans streptococci, Streptococcus pyogenes,
and Streptococcus bovis (8). Further studies from that group
showed that there was a species variation in the amount of free
fatty acids recovered in the surfactant preparation of bron-
choalveolar lavage fluid, which could explain the difference in
S. pneumoniae killing between this rat surfactant and surfac-
tant prepared from bronchoalveolar lavage fluid from guinea
pigs (7). Enhancement of growth has been found for Esche-
richia coli and viridans streptococci with a crude surfactant
preparation from dogs (18) and for S. aureus with a surfactant
from rabbits (23). Studies with human alveolar lining material
showed that incubation of S. pneumoniae or Haemophilus in-
fluenzae with the alveolar lining material had no effect on the
viabilities of these bacteria; in fact, alveolar lining material
supported the replication of H. influenzae (19). In the present
study, no effect of surfactant on the growth of K. pneumoniae,
P. aeruginosa, or S. aureus was found. Our results show no S.
pneumoniae killing by surfactant. S. pneumoniae growth was
not affected by surfactant except for a decrease in the growth
rate in THB with both surfactant and rabbit serum compared
with the growth rates in THB with rabbit serum. The surfactant
used in our study is a highly purified extraction from bovine
lungs, which could explain the observed conflicting results on
S. pneumoniae growth. It is comparable to the commercially
available surfactants which are used for the treatment of infant
respiratory distress syndrome. The concentration of 25 mg/ml
is based on the current surfactant concentrations used for
surfactant replacement therapy (12).
Preliminary results (45a) on S. pneumoniae growth in the
presence of surfactant showed a stimulation of growth com-
pared with S. pneumoniae growth in unsupplemented THB. In
the present study this could not be supported by the data. For
optimal S. pneumoniae growth, THB is generally supplemented
with serum. These preliminary results provided the rationale
for studying S. pneumoniae killing in both THB and THB
supplemented with rabbit serum. Moreover, serum is known to
inhibit the functional integrity of pulmonary surfactant (15),
and this, too, could interfere in a surfactant-antibiotic interac-
tion.
In two animal models of respiratory failure caused by Pneu-
mocystis carinii or influenza A virus, endotracheal instillation
of exogenous surfactant restored lung function and gas ex-
change within 30 min (11, 45). These results, together with the
histological findings in those studies, show that surfactant can
reopen atelectatic areas. With a surfactant-antibiotic mixture it
is expected that a large antibiotic dosage can be delivered to
the lung in nonaereated areas, which are often infected areas.
The use of surfactant mixed with antibiotics therefore seems to
be a promising therapeutic approach in patients with severe
pneumonia.
Whether the partial inactivation of tobramycin by surfactant
can be compensated for by higher antibiotic dosages without
an increased risk for toxic systemic levels needs further inves-
tigation in vivo. Future investigations should also focus on
whether the function of surfactant remains unchanged after it
is mixed with antibiotics, since this, too, could limit the use of
a surfactant-antibiotic mixture.
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